

Krystyna Pawlak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8260626/publications.pdf>

Version: 2024-02-01

150
papers

3,755
citations

147566

31
h-index

168136

53
g-index

151
all docs

151
docs citations

151
times ranked

5022
citing authors

#	ARTICLE	IF	CITATIONS
1	Benzophenone-3, a chemical UV-filter in cosmetics: is it really safe for children and pregnant women?. <i>Postepy Dermatologii i Alergologii</i> , 2022, 39, 26-33.	0.4	15
2	Indoleamine 2,3 Dioxygenase – The Potential Link between the Innate Immunity and the Ischemia-Reperfusion-Induced Acute Kidney Injury?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6176.	1.8	4
3	Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 535-548.	2.5	18
4	Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease – Apart or Together?. <i>Nutrients</i> , 2021, 13, 809.	1.7	15
5	MO564CHRONIC EXPOSURE TO INDOXYL SULFATE CHANGES BONE PROPERTIES AND EXPRESSION OF SIRT2, SIRT3, AND SIRT7 GENES*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
6	Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6563.	1.8	3
7	MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3203.	1.7	9
8	Preclinical Toxicity and Safety of MM-129 – First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. <i>Pharmaceutics</i> , 2021, 13, 1222.	2.0	6
9	Serum PTH, PTH1R/ATF4 pathway, and the sRANKL/OPG system in bone as a new link between bone growth, cross-sectional geometry, and strength in young rats with experimental chronic kidney disease. <i>Cytokine</i> , 2021, 148, 155685.	1.4	2
10	P0871THE IMPACT OF ENDOGENOUS PTH/PTH1R/ATF4 AXIS ON TRABECULAR AND CORTICAL BONE REMODELING AND BONE GROWTH OF YOUNG RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASES. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
11	P0690CORRELATIONS BETWEEN OPG/RANKL/RANK AXIS, VITAMIN D STATUS, PTH AND VASCULAR CALCIFICATION IN AN ADENINE-INDUCED MODEL OF CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	3
12	Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5979.	1.8	6
13	The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1697-1711.	2.5	4
14	P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
15	P0874THE IMPACT OF CHRONIC EXPOSURE TO INDOXYL SULFATE ON BONE TURNOVER MARKERS, PTH, VITAMIN D3, AND BIOMECHANICAL AND DENSITOMETRIC PROPERTIES OF BONES IN RAT MODEL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
16	Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165528.	1.8	4
17	FP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
18	The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 353-364.	1.5	3

#	ARTICLE	IF	CITATIONS
19	The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease. <i>International Urology and Nephrology</i> , 2019, 51, 491-502.	0.6	6
20	Probiotic <i>Lactobacillus Plantarum</i> 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. <i>Psychoneuroendocrinology</i> , 2019, 100, 213-222.	1.3	295
21	RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. <i>Cytokine</i> , 2018, 106, 19-28.	1.4	12
22	Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease. <i>International Urology and Nephrology</i> , 2018, 50, 127-135.	0.6	19
23	Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer. <i>British Journal of Pharmacology</i> , 2018, 175, 743-762.	2.7	16
24	Indoxyl Sulfate Promotes Arterial Thrombosis in Rat Model via Increased Levels of Complex TF/VII, PAI-1, Platelet Activation as Well as Decreased Contents of SIRT1 and SIRT3. <i>Frontiers in Physiology</i> , 2018, 9, 1623.	1.3	37
25	LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys. <i>Bone</i> , 2018, 113, 124-136.	1.4	10
26	Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1262.	1.8	5
27	The activation of the kynurenine pathway in a rat model with renovascular hypertension. <i>Experimental Biology and Medicine</i> , 2017, 242, 750-761.	1.1	25
28	Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review. <i>Advances in Medical Sciences</i> , 2017, 62, 52-64.	0.9	16
29	The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease. <i>Bone</i> , 2017, 105, 1-10.	1.4	23
30	Indoxyl sulfate – the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2017, 18, 35.	0.8	78
31	Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. <i>Frontiers in Physiology</i> , 2017, 8, 836.	1.3	34
32	Immune suppression of IgG response against dairy proteins in major depression. <i>BMC Psychiatry</i> , 2017, 17, 268.	1.1	17
33	Erythropoietin Enhances the Cytotoxic Effect of Hydrogen Peroxide on Colon Cancer Cells. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 127-137.	0.9	6
34	A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. <i>PeerJ</i> , 2017, 5, e3199.	0.9	7
35	Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts. <i>Molecular and Cellular Biochemistry</i> , 2016, 421, 1-18.	1.4	27
36	The Biomechanical Testing for the Assessment of Bone Quality in an Experimental Model of Chronic Kidney Disease. <i>Nephron</i> , 2016, 132, 51-58.	0.9	22

#	ARTICLE	IF	CITATIONS
37	The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite " 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney Disease. PLoS ONE, 2016, 11, e0163526.	1.1	23
38	Endocan " the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease. Clinical Biochemistry, 2015, 48, 425-430.	0.8	33
39	oxLDL " the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients. Thrombosis Research, 2014, 134, 711-716.	0.8	3
40	Effect of diabetes and oxidative stress on plasma CCL23 levels in patients with severe chronic kidney disease. Polish Archives of Internal Medicine, 2014, 124, 459-466.	0.3	8
41	Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio " Are they real oxidative stress markers in dialyzed patients?. Life Sciences, 2013, 92, 253-258.	2.0	25
42	YKL-40 in hemodialyzed patients with and without cardiovascular complications " The enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine, 2013, 62, 75-80.	1.4	11
43	Oxidized LDL to autoantibodies against oxLDL ratio " The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis, 2012, 224, 252-257.	0.4	36
44	Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?. Translational Research, 2012, 160, 346-354.	2.2	25
45	Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis. Thrombosis Research, 2012, 129, 704-709.	0.8	12
46	The alteration in Cu/Zn superoxide dismutase and adhesion molecules concentrations in diabetic patients with chronic kidney disease: The effect of dialysis treatment. Diabetes Research and Clinical Practice, 2012, 98, 264-270.	1.1	11
47	Interleukin-21 in hemodialyzed patients: Association with the etiology of chronic kidney disease and the seropositivity against hepatitis C virus infection. Clinical Biochemistry, 2011, 44, 1416-1420.	0.8	6
48	IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report. Oncology Letters, 2011, 2, 1155-1159.	0.8	11
49	Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clinical Biochemistry, 2011, 44, 838-843.	0.8	41
50	Relationships between Insulin-Like Growth Factor I and Selected Clinico-Morphological Parameters in Colorectal Cancer Patients. Polski Przegląd Chirurgiczny, 2011, 83, 250-7.	0.2	7
51	Hyperfibrinolysis, uPA/suPAR System, Kynurenines, and the Prevalence of Cardiovascular Disease in Patients With Chronic Renal Failure on Conservative Treatment. American Journal of the Medical Sciences, 2010, 339, 5-9.	0.4	284
52	3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1 ² (CCL4) in patients with chronic kidney disease. Clinical Biochemistry, 2010, 43, 1101-1106.	0.8	17
53	Impact of residual renal function and HCV seropositivity on plasma CD40/CD40L system and oxidative status in haemodialysis patients. Clinical Biochemistry, 2010, 43, 1393-1398.	0.8	5
54	Systemic Levels of MMP2/TIMP2 and Cardiovascular Risk in CAPD Patients. Nephron Clinical Practice, 2010, 115, c251-c258.	2.3	18

#	ARTICLE	IF	CITATIONS
55	Effect of Sulodexide on Plasma Transforming Growth Factor- β 1 in Healthy Volunteers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 60-65.	0.7	8
56	Kynurenine and its metabolites in Alzheimer's disease patients. <i>Advances in Medical Sciences</i> , 2010, 55, 204-211.	0.9	215
57	Kynurenine pathway – a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. <i>Advances in Medical Sciences</i> , 2010, 55, 196-203.	0.9	75
58	Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. <i>Thrombosis Research</i> , 2010, 125, e40-e45.	0.8	25
59	Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas – the new putative determinants of endothelial dysfunction in haemodialysis patients. <i>Thrombosis Research</i> , 2010, 126, 393-398.	0.8	5
60	Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer – evaluation of the prognostic significance of these agents. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1439-45.	1.4	3
61	Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 84-91.	0.7	12
62	Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: A cross-over study. <i>Thrombosis Research</i> , 2009, 123, 631-636.	0.8	7
63	Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. <i>Thrombosis Research</i> , 2009, 124, 452-457.	0.8	31
64	Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. <i>Thrombosis and Haemostasis</i> , 2009, 102, 49-55.	1.8	41
65	The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. <i>Atherosclerosis</i> , 2009, 204, 309-314.	0.4	107
66	Kynurenine, quinolinic acid – The new factors linked to carotid atherosclerosis in patients with end-stage renal disease. <i>Atherosclerosis</i> , 2009, 204, 561-566.	0.4	73
67	Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 590-594.	0.5	35
68	Kynurenine and Its Metabolites – Kynurenic Acid and Anthranilic Acid are Associated With Soluble Endothelial Adhesion Molecules and Oxidative Status in Patients With Chronic Kidney Disease. <i>American Journal of the Medical Sciences</i> , 2009, 338, 293-300.	0.4	31
69	Tissue factor pathway inhibitor release and depletion by sulodexide in humans. <i>Advances in Medical Sciences</i> , 2009, 54, 32-6.	0.9	10
70	Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients.. <i>Folia Histochemica Et Cytobiologica</i> , 2009, 46, 487-92.	0.6	8
71	Soluble angiogenesis markers in gastric tumor patients.. <i>Folia Histochemica Et Cytobiologica</i> , 2009, 47, 81-6.	0.6	11
72	Combined perioperative plasma endoglin and VEGF-a assessment in colorectal cancer patients.. <i>Folia Histochemica Et Cytobiologica</i> , 2009, 47, 231-6.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. <i>Nephrology</i> , 2008, 13, 153-156.	0.7	63
74	Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. <i>Advances in Medical Sciences</i> , 2008, 53, 32-6.	0.9	34
75	NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: Are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine?. <i>International Journal of Cardiology</i> , 2008, 127, 290-291.	0.8	67
76	Endothelial Function and Novel Adhesion Molecule CD44 in Kidney Allograft Recipients. <i>Transplantation Proceedings</i> , 2008, 40, 3470-3473.	0.3	10
77	Apelin, a Novel Adipocytokine, in Relation to Endothelial Function and Inflammation in Kidney Allograft Recipients. <i>Transplantation Proceedings</i> , 2008, 40, 3466-3469.	0.3	44
78	Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. <i>Thrombosis Research</i> , 2008, 121, 543-548.	0.8	16
79	Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients. <i>Thrombosis Research</i> , 2008, 121, 787-791.	0.8	1
80	The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. <i>Thrombosis Research</i> , 2008, 122, 328-335.	0.8	25
81	Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. <i>Thrombosis Research</i> , 2008, 123, 166-170.	0.8	11
82	Prohepcidin in pregnancy: Acute phase protein, marker of iron metabolism, or both?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 140, 293-294.	0.5	2
83	Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. <i>Cytokine</i> , 2008, 43, 98-101.	1.4	34
84	Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 338-345.	0.7	9
85	Hepcidin is Linked to Anemia and Inflammation in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2008, 28, 418-421.	1.1	9
86	Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF- β 1 during haemodialysis: a cross-over study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1690-1696.	0.4	9
87	Long-Term Erythropoietin Therapy Does Not Affect Metalloproteinases and Their Inhibitor Levels, Oxidative Stress and Inflammation in Hemodialyzed Patients. <i>American Journal of Nephrology</i> , 2007, 27, 221-225.	1.4	5
88	Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values?. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 408-415.	0.9	98
89	Erythropoietin Therapy Decreased Tissue Factor, Its Pathway Inhibitor, and Oxidative Stress in Peritoneal Dialysis Patients with Diabetes. <i>Nephron Clinical Practice</i> , 2007, 107, c20-c25.	2.3	3
90	Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 467-471.	0.5	9

#	ARTICLE	IF	CITATIONS
91	Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. <i>Thrombosis Research</i> , 2007, 119, 475-480.	0.8	15
92	Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. <i>Thrombosis Research</i> , 2007, 120, 871-876.	0.8	22
93	Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. <i>Thrombosis Research</i> , 2007, 120, 797-803.	0.8	18
94	Chronic viral hepatitis and iron affect the plasma levels of LIGHT—a new member of the TNF superfamily in uraemic haemodialyzed patients. <i>Cytokine</i> , 2007, 39, 201-206.	1.4	2
95	Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study. <i>Cytokine</i> , 2007, 40, 98-104.	1.4	4
96	Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. <i>Atherosclerosis</i> , 2007, 190, 199-204.	0.4	51
97	Markers of Bone Metabolism in Hemodialyses and Hemodiafiltration. <i>Renal Failure</i> , 2007, 29, 595-601.	0.8	4
98	Thyroid Function, Endothelium, and Inflammation in Hemodialyzed Patients: Possible Relations?. , 2007, 17, 30-37.		22
99	Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. <i>Clinical Biochemistry</i> , 2007, 40, 81-85.	0.8	36
100	LIGHT—A new member of the TNF superfamily in the plasma, dialysate and urine of uremic patients; the impact of residual diuresis and presence of viral hepatitis. <i>Clinical Biochemistry</i> , 2007, 40, 1240-1244.	0.8	0
101	Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. <i>Nephrology</i> , 2007, 12, 246-253.	0.7	23
102	Sulodexide induces hepatocyte growth factor release in humans. <i>European Journal of Pharmacology</i> , 2007, 558, 167-171.	1.7	20
103	Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II. <i>Journal of Nephrology</i> , 2007, 20, 370-2.	0.9	8
104	Carotid atherosclerosis is associated with enhanced β^2 -chemokine levels in patients on continuous ambulatory peritoneal dialysis. <i>Atherosclerosis</i> , 2006, 186, 146-151.	0.4	19
105	Inflammation but not oxidative stress is associated with β^2 -chemokine levels and prevalence of cardiovascular disease in uraemic patients. <i>Cytokine</i> , 2006, 35, 258-262.	1.4	15
106	Oxidative stress effects fibrinolytic system in dialysis uraemic patients. <i>Thrombosis Research</i> , 2006, 117, 517-522.	0.8	24
107	Hepcidin, an Acute-Phase Protein and a Marker of Inflammation in Kidney Transplant Recipients With and Without Coronary Artery Disease. <i>Transplantation Proceedings</i> , 2006, 38, 2895-2898.	0.3	27
108	Possible Relations Between Thyroid Function, Endothelium, and Kidney and Liver Function in Kidney Allograft Recipients. <i>Transplantation Proceedings</i> , 2006, 38, 3509-3513.	0.3	14

#	ARTICLE	IF	CITATIONS
109	Resistin, a New Adipokine, Is Related to Inflammation and Renal Function in Kidney Allograft Recipients. <i>Transplantation Proceedings</i> , 2006, 38, 3434-3436.	0.3	33
110	Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3450-3457.	0.4	5
111	Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. <i>American Journal of Hematology</i> , 2006, 81, 832-837.	2.0	87
112	Long-Term Erythropoietin Therapy Decreases CC-Chemokine Levels and Intima-Media Thickness in Hemodialyzed Patients. <i>American Journal of Nephrology</i> , 2006, 26, 497-502.	1.4	9
113	TGF- β 1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 493-494.	0.7	1
114	Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients. <i>Medical Science Monitor</i> , 2006, 12, CR181-5.	0.5	13
115	Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. <i>Journal of Nephrology</i> , 2006, 19, 150-4.	0.9	12
116	Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. <i>Clinical Biochemistry</i> , 2005, 38, 700-705.	0.8	50
117	Anthranilic Acid--uraemic Toxin Damaged Red Cell's Membrane. <i>International Urology and Nephrology</i> , 2005, 37, 621-627.	0.6	8
118	Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?. <i>American Journal of Nephrology</i> , 2005, 25, 586-590.	1.4	56
119	Circulating β -chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients -- Role of oxidative stress. <i>Cytokine</i> , 2005, 31, 18-24.	1.4	18
120	Correlations Between Leptin, Body Composition, Bone Mineral Density, and Bone Metabolism in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2005, 37, 2151-2153.	0.3	8
121	Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients. <i>Thrombosis and Haemostasis</i> , 2004, 92, 646-653.	1.8	17
122	Oxidative Stress Influences CC-Chemokine Levels in Hemodialyzed Patients. <i>Nephron Physiology</i> , 2004, 96, p105-p112.	1.5	24
123	Oxidative Stress -- a Link between Endothelial Injury, Coagulation Activation, and Atherosclerosis in Haemodialysis Patients. <i>American Journal of Nephrology</i> , 2004, 24, 154-161.	1.4	66
124	Possible New Role of Monocyte Chemoattractant Protein-1 in Hemodialysis Patients with Cardiovascular Disease. <i>American Journal of Nephrology</i> , 2004, 24, 635-640.	1.4	14
125	Comparison of Effects of Different Heparins on Thrombin Activatable Fibrinolysis Inhibitor in Hemodialyzed Patients. <i>American Journal of Nephrology</i> , 2004, 24, 624-629.	1.4	12
126	Hepatitis intensified oxidative stress, MIP-1 β and RANTES plasma levels in uraemic patients. <i>Cytokine</i> , 2004, 28, 197-204.	1.4	29

#	ARTICLE	IF	CITATIONS
127	Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. <i>Thrombosis Research</i> , 2003, 109, 247-251.	0.8	27
128	RELATIONS BETWEEN OXIDATIVE STRESS, HEPATOCYTE GROWTH FACTOR, AND LIVER DISEASE IN HEMODIALYSIS PATIENTS. <i>Renal Failure</i> , 2002, 24, 825-837.	0.8	11
129	Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 526-528.	0.4	6
130	Effect of Hemodialysis on Plasma Levels of Vascular Endothelial Markers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 245-250.	0.7	11
131	Inflammatory Markers and Platelet Aggregation Tests as Predictors of Hemoglobin and Endogenous Erythropoietin Levels in Hemodialysis Patients. <i>Nephron</i> , 2002, 91, 671-681.	0.9	12
132	Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1442-1447.	0.4	42
133	Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 787-792.	0.4	18
134	Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. <i>Clinical Transplantation</i> , 2001, 15, 349-353.	0.8	7
135	Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. <i>International Urology and Nephrology</i> , 2001, 33, 399-404.	0.6	80
136	A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1692-1696.	0.4	22
137	Importance of Serotonergic Mechanisms in the Thrombotic Complications in Hemodialyzed Patients Treated with Erythropoietin. <i>Nephron</i> , 2000, 84, 305-311.	0.9	21
138	Comparison of Different Assays for von Willebrand Factor in Hemodialysis Patients. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 308-315.	0.5	1
139	A Potent 5-Hydroxytryptamine Receptor (5-HT _{2A}) Antagonist, DV-7028, Delays Arterial Thrombosis Development in Rats. <i>Thrombosis Research</i> , 1998, 90, 259-270.	0.8	18
140	Long-term Effects of Erythropoietin on Platelet Serotonin Storage and Platelet Aggregation in Hemodialysis Patients with Reference to Ketanserin Treatment. <i>Thrombosis Research</i> , 1998, 90, 171-180.	0.8	9
141	PERIPHERAL SEROTONERGIC SYSTEM IN UREMIA. <i>Thrombosis Research</i> , 1996, 83, 189-194.	0.8	17
142	HEMOSTASIS, PLATELET FUNCTION AND SEROTONIN IN ACUTE AND CHRONIC RENAL FAILURE. <i>Thrombosis Research</i> , 1996, 83, 351-361.	0.8	76
143	Ketanserin and Erythropoiesis in Hemodialysis Patients with Polycystic Kidneys. <i>American Journal of Nephrology</i> , 1996, 16, 451-452.	1.4	3
144	Erythropoietin and uremic platelet aggregation in vivo and in vitro. <i>International Journal of Clinical and Laboratory Research</i> , 1996, 26, 199-202.	1.0	3

#	ARTICLE	IF	CITATIONS
145	Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 2444-2448.	0.4	6
146	Antithrombotic Activity of Dermatan Sulphates, Heparins and their Combination in an Animal Model of Arterial Thrombosis. <i>Thrombosis and Haemostasis</i> , 1996, 76, 1102-1107.	1.8	14
147	THE COAGULO-LYTIC SYSTEM AND ENDOTHELIAL FUNCTION IN CYCLOSPORINE-TREATED KIDNEY ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1996, 62, 828-830.	0.5	70
148	Ketanserin Lowers Erythropoietin Concentration in Hemodialyzed Patients Treated with the Hormone. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 621-626.	0.8	6
149	Effect of ketanserin on platelet function and bleeding time in uremic patients treated with erythropoietin. <i>Thrombosis Research</i> , 1995, 78, 541-546.	0.8	2
150	Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 42-44.	1.0	9